Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Text-based Reduction Intervention for Smokeless Tobacco Cessation- Pilot Study

NCT06637358
View directory record Official record
Conditions
Smokeless Tobacco Cessation
Interventions
Extended Scheduled Gradual Reduction (SGR), Quit Coach
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00554385
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 12 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
23
States / cities
Little Rock, Arkansas • Boulder, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

NCT02782715
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Stereotactic Body Radiation Therapy (SBRT), Microwave Ablation (MWA)
Radiation · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

NCT02537015
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 18, 2026, 4:26 AM EDT
Active, not recruiting No phase listed Observational

IN.PACT™ AV Access Post-Approval Study (PAS002)

NCT04543539
View directory record Official record
Conditions
Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Interventions
IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Combination Product
Lead sponsor
Medtronic
Industry
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 18, 2026, 4:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults

NCT07530900
View directory record Official record
Conditions
Healthy Volunteers, Speech
Interventions
Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Results available

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Not applicable Interventional

Influence of Opioid Use on the Effects of Spinal Manipulative Therapy for Low Back Pain

NCT03749564
View directory record Official record
Conditions
Low Back Pain, Opioid Use
Interventions
SMT, Activation Exercises, Mobilizing Exercises, Extended SMT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Young Adults' Responses to Anti-smoking Messages

NCT01954407
View directory record Official record
Conditions
Smoking
Interventions
Smoking-Related Messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 25 Years
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Perception on Medical Extended Reality Devices

NCT05479019
View directory record Official record
Conditions
Healthy
Interventions
Visual stimuli
Behavioral
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

NCT03638128
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
Denosumab, Alternative osteoporosis medications
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II

NCT07205367
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Zio Monitor
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
San Francisco, California • Deerfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 4:26 AM EDT
Terminated Phase 1 Interventional Results available

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

NCT02702492
View directory record Official record
Conditions
Solid Tumors, NHL
Interventions
KPT-9274, Niacin ER, Nivolumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

NCT04657198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine (GSK3844766A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 18, 2026, 4:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Vibration on Motor Function of Survivors of Chronic Stroke

NCT06663501
View directory record Official record
Conditions
Stroke, Healthy
Interventions
Assisted Motion with Enhanced Sensation training
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

NCT00566501
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 91 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 18, 2026, 4:26 AM EDT
Recruiting Phase 3 Interventional

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Tulisokibart, Placebo to tulisokibart
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Not listed
Enrollment
1,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
12
States / cities
Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 4:26 AM EDT
Active, not recruiting Phase 3 Interventional

Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00355134
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 18, 2026, 4:26 AM EDT
Not listed Not applicable Interventional

Cerebral Palsy Upper Extremity Orthotic Device

NCT05024409
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Orthotic, Occupational Therapy
Device · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
4 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Newark, New Jersey • Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 18, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 18, 2026, 4:26 AM EDT